Cannabis Industry Insights

As Rescheduling Inches Forward, Its Opponents Open a New Front in Court

Trulieve Rings the NYSE Bell — and the Industry Discovers Wall Street Was Never the Hard Part

For more than a decade, the dream of every American cannabis executive sounded roughly the same: someday, a plant-touching operator would trade on a major U.S. stock exchange like any other consumer business.

800 Milligrams of CBD and a Hard Truth About What Cannabis Can and Can't Treat

For the millions of people living with the relentless nerve pain that follows a spinal cord injury, the options have always been grim

The Sober-Curious Cannabis Drink Has Its Data — and a Big Week of Launches to Match

The most important cannabis product of the week wasn't a flashy new strain or a celebrity edible. It was a spreadsheet. On June 4, MoreBetter and the Network of Applied Pharmacognosy released findings from the largest real-world cannabis beverage study to date.

The Clock Is Ticking on Two Fronts: A June Hearing for Marijuana, a July Deadline for Hemp

Cannabis policy in America has rarely felt as bifurcated as it does this week. On one track, marijuana is moving — haltingly, contentiously — toward looser federal control. On another, the hemp-derived products that have flooded gas stations and smoke shops are being squeezed toward extinction.

Cannabis Stocks Land on Robinhood as Alabama Cuts the Ribbon

For years, the American cannabis industry has operated like a business hiding in plain sight: legal in most states, banned by the federal government, and walled off from the ordinary machinery of capital and commerce. This week, two of those walls quietly came down at once.

A Brownie, a Drink, and a Driving Test That Doesn't Work: The Week's Most Important Cannabis Science

Science can sometimes feel like it moves slower than the culture around it. For cannabis, that gap has been a defining feature of the last decade — millions of Americans using a substance while the research needed to understand its risks and benefits lags years, sometimes decades, behind the conversation.

Vapes, Pre-Rolls, and the Price of Progress: What This Week's Product Moves Say About Where Cannabis Is Headed

Cannabis product news this week told a story that has become increasingly familiar in 2026: the industry is maturing fast, but it's doing so unevenly, with some categories racing ahead while others fight for shelf space in an increasingly crowded market.

The DEA Hearing Is Six Weeks Away. Here's What That Actually Means for Cannabis.

The clock is now running on one of the most consequential proceedings in American drug policy history. The Drug Enforcement Administration's formal hearing on whether to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act is officially set to begin.

Curaleaf's Stock Move, New York's $3.3 Billion Milestone, and the Rise of the Digital Dispensary Shopper

The cannabis industry had a week of quiet but consequential momentum, driven less by splashy announcements than by the accumulating weight of numbers that are starting to tell a coherent story: markets are maturing, winners are consolidating their positions, and the question of who survives the next two years is coming into sharper focus.